Nonclinical biodistribution, integration, and toxicology evaluations of an H5N1 pandemic influenza plasmid dna vaccine formulated with vaxfectin®

Vaccine

Volumn 29, Issue 33, 2011, Pages 5443-5452

  Doukas, John ^a   Morrow, Jane ^a   Bellinger, Dawn ^a   Hilgert, Thomas ^a   Martin, Terrie ^a   Jones, Doug ^a   Mahajan, Rohit ^a   Rusalov, Denis ^a   Sullivan, Sean ^a   Rolland, Alain ^a  

^a VICAL INC   (United States)

Author keywords

Adjuvant; Influenza; Plasmid

Indexed keywords

ADJUVANT; DNA VACCINE; UNCLASSIFIED DRUG; VAXFECTIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; DNA INTEGRATION; DOSE RESPONSE; DRUG DISTRIBUTION; DRUG EFFECT; EDEMA; ERYTHEMA; EXPERIMENTAL RABBIT; FEMALE; IMMUNE RESPONSE; MALE; NONHUMAN; PRIORITY JOURNAL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INJECTIONS, INTRAMUSCULAR; MALE; PHOSPHATIDYLETHANOLAMINES; RABBITS; VACCINES, DNA;

EID: 79960390195     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.05.060     Document Type: Article

References (38)

1. Wolff J.A., Malone R.W., Williams P., Chong W., Acsadi G., Jani A., et al. Direct gene transfer into mouse muscle in vivo. Science 1990, 247(4949 Pt 1):1465-1468.
2. Lu S., Wang S., Grimes-Serrano J.M. Current progress of DNA vaccine studies in humans. Expert Rev Vaccines 2008, 7(2):175-191.
3. Hartikka J., Bozoukova V., Ferrari M., Sukhu L., Enas J., Sawdey M., et al. Vaxfectin enhances the humoral immune response to plasmid DNA-encoded antigens. Vaccine 2001, 19(15-16):1911-1923.
4. Hartikka J., Bozoukova V., Yang C.K., Ye M., Rusalov D., Shlapobersky M., et al. Vaxfectin, a cationic lipid-based adjuvant for protein-based influenza vaccines. Vaccine 2009, 27(46):6399-6403.
5. Mahato R.I., Rolland A., Tomlinson E. Cationic lipid-based gene delivery systems: pharmaceutical perspectives. Pharm Res 1997, 14(7):853-859.
6. Reyes L., Hartikka J., Bozoukova V., Sukhu L., Nishioka W., Singh G., et al. Vaxfectin enhances antigen specific antibody titers and maintains Th1 type immune responses to plasmid DNA immunization. Vaccine 2001, 19(27):3778-3786.
7. Vilalta A., Shlapobersky M., Wei Q., Planchon R., Rolland A., Sullivan S. Analysis of biomarkers after intramuscular injection of Vaxfectin-formulated hCMV gB plasmid DNA. Vaccine 2009, 27(52):7409-7417.
8. Sullivan S.M., Doukas J., Hartikka J., Smith L., Rolland A., Vaxfectin: a versatile adjuvant for plasmid DNA- and protein-based vaccines. Expert Opin Drug Deliv 2010, 7(12):1433-1446.
9. Hermanson G., Whitlow V., Parker S., Tonsky K., Rusalov D., Ferrari M., et al. A cationic lipid-formulated plasmid DNA vaccine confers sustained antibody-mediated protection against aerosolized anthrax spores. Proc Natl Acad Sci USA 2004, 101(37):13601-13606.
10. Locher C.P., Witt S.A., Ashlock B.M., Polacino P., Hu S.L., Shiboski S., et al. Human immunodeficiency virus type 2 DNA vaccine provides partial protection from acute baboon infection. Vaccine 2004, 22(17-18):2261-2272.
11. Hahn U.K., Aichler M., Boehm R., Beyer W. Comparison of the immunological memory after DNA vaccination and protein vaccination against anthrax in sheep. Vaccine 2006, 24(21):4595-4597.
12. Sedegah M., Rogers W.O., Belmonte A., Belmonte M., Banania G., Patterson N., et al. Vaxfectin enhances immunogenicity and protective efficacy of P. yoelii circumsporozoite DNA vaccines. Vaccine 2006, 24(11):1921-1927.
13. Jimenez G.S., Planchon R., Wei Q., Rusalov D., Geall A., Enas J., et al. Vaxfectin-formulated influenza DNA vaccines encoding NP and M2 viral proteins protect mice against lethal viral challenge. Hum Vaccin 2007, 3(5):157-164.
14. Lalor P.A., Webby R.J., Morrow J., Rusalov D., Kaslow D.C., Rolland A., et al. Plasmid DNA-based vaccines protect mice and ferrets against lethal challenge with A/Vietnam/1203/04 (H5N1) influenza virus. J Infect Dis 2008, 197(12):1643-1652.
15. Pan C.H., Jimenez G.S., Nair N., Wei Q., Adams R.J., Polack F.P., et al. Use of Vaxfectin adjuvant with DNA vaccine encoding the measles virus hemagglutinin and fusion proteins protects juvenile and infant rhesus macaques against measles virus. Clin Vaccine Immunol 2008, 15(8):1214-1221.
16. Smith L.R., Wloch M.K., Ye M., Reyes L.R., Boutsaboualoy S., Dunne C.E., et al. Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin. Vaccine 2010, 28(13):2565-2572.
17. Vilalta A., Mahajan R., Hartikka J., Leamy V., Martin T., Rusalov D., et al. II. Cationic lipid-formulated plasmid DNA-based Bacillus anthracis vaccine: evaluation of plasmid DNA persistence and integration potential. Hum Gene Ther 2005, 16(10):1151-1156.
18. Vilalta A., Mahajan R.K., Hartikka J., Rusalov D., Martin T., Bozoukova V., et al. I. Poloxamer-formulated plasmid DNA-based human cytomegalovirus vaccine: evaluation of plasmid DNA biodistribution/persistence and integration. Hum Gene Ther 2005, 16(10):1143-1150.
19. Martin T., Parker S.E., Hedstrom R., Le T., Hoffman S.L., Norman J., et al. Plasmid DNA malaria vaccine: the potential for genomic integration after intramuscular injection. Hum Gene Ther 1999, 10(5):759-768.
20. Draize J.H., Dermal, Toxicity Appraisal of the safety of chemicals in food, drugs and cosmetics 1959, The Association of Food and Drug Officials of the United States, Bureau of Food and Drugs, Austin, TX, p. 46-59.
21. Nichols W.W., Ledwith B.J., Manam S.V., Troilo P.J. Potential DNA vaccine integration into host cell genome. Ann N Y Acad Sci 1995, 772:30-39.
22. Sheets R.L., Stein J., Manetz T.S., Duffy C., Nason M., Andrews C., et al. Biodistribution of DNA plasmid vaccines against HIV-1, Ebola Severe Acute Respiratory Syndrome, or West Nile virus is similar, without integration, despite differing plasmid backbones or gene inserts. Toxicol Sci 2006, 91(2):610-619.
23. Wang Z., Troilo P.J., Wang X., Griffiths T.G., Pacchione S.J., Barnum A.B., et al. Detection of integration of plasmid DNA into host genomic DNA following intramuscular injection and electroporation. Gene Ther 2004, 11(8):711-721.
24. Wolff J.A., Ludtke J.J., Acsadi G., Williams P., Jani A. Long-term persistence of plasmid DNA and foreign gene expression in mouse muscle. Hum Mol Genet 1992, 1(6):363-369.
25. Manam S., Ledwith B.J., Barnum A.B., Troilo P.J., Pauley C.J., Harper L.B., et al. vaccines: tissue distribution and effects of DNA sequence, adjuvants and delivery method on integration into host DNA. Intervirology 2000, 43(4-6):273-281.
26. Leamy V.L., Martin T., Mahajan R., Vilalta A., Rusalov D., Hartikka J., et al. Comparison of rabbit and mouse models for persistence analysis of plasmid-based vaccines. Hum Vaccin 2006, 2(3):113-118.
27. Sheets R.L., Stein J., Manetz T.S., Andrews C., Bailer R., Rathmann J., et al. Toxicological safety evaluation of DNA plasmid vaccines against HIV-1, Ebola Severe Acute Respiratory Syndrome, or West Nile virus is similar despite differing plasmid backbones or gene-inserts. Toxicol Sci 2006, 91(2):620-630.
28. Keitel W.A., Treanor J.J., El Sahly H.M., Evans T.G., Kopper S., Whitlow V., et al. Evaluation of a plasmid DNA-based anthrax vaccine in rabbits, nonhuman primates and healthy adults. Hum Vaccin 2009, 5(8):536-544.
29. Abdel-Ghafar A.N., Chotpitayasunondh T., Gao Z., Hayden F.G., Nguyen D.H., de Jong M.D., et al. Update on avian influenza A (H5N1) virus infection in humans. N Engl J Med 2008, 358(3):261-273.
30. Lin J., Zhang J., Dong X., Fang H., Chen J., Su N., et al. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial. Lancet 2006, 368(9540):991-997.
31. Stephenson I., Nicholson K.G., Gluck R., Mischler R., Newman R.W., Palache A.M., et al. Safety and antigenicity of whole virus and subunit influenza A/Hong Kong/1073/99 (H9N2) vaccine in healthy adults: phase I randomised trial. Lancet 2003, 362(9400):1959-1966.
32. Treanor J.J., Campbell J.D., Zangwill K.M., Rowe T., Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 2006, 354(13):1343-1351.
33. Bresson J.L., Perronne C., Launay O., Gerdil C., Saville M., Wood J., et al. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 2006, 367(9523):1657-1664.
34. Treanor J.J., Wilkinson B.E., Masseoud F., Hu-Primmer J., Battaglia R., O'Brien D., et al. Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine 2001, 19(13-14):1732-1737.
35. Keitel W.A., Atmar R.L. Vaccines for pandemic influenza: summary of recent clinical trials. Curr Top Microbiol Immunol 2009, 333:431-451.
36. Stephenson I., Nicholson K.G., Colegate A., Podda A., Wood J., Ypma E., et al. Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population. Vaccine 2003, 21(15):1687-1693.
37. Stephenson I., Bugarini R., Nicholson K.G., Podda A., Wood J.M., Zambon M.C., et al. Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. J Infect Dis 2005, 191(8):1210-1215.
38. Nicholson K.G., Colegate A.E., Podda A., Stephenson I., Wood J., Ypma E., et al. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 2001, 357(9272):1937-1943.